Truist reiterates Buy on Scholar Rock stock, cites uptake potential

Truist Securities reiterated a Buy rating and $77 price target for Scholar Rock (SRRK), citing potential uptake of its Isembyld treatment for spinal muscular atrophy. Analysts expect 50-60% of patients to use the drug within five years, with key opinion leaders validating trial results and noting functional improvements. The stock trades at $41.14, with a Strong Buy consensus and price targets ranging from $58 to $84.

Original reporting
Published Oct 20, 2026, 2:14 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 20, 2026, 2:32 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$SRRK
Bullish
medium confidence
Mentioned
$SRRK
Relevance
4/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$SRRKBullishLow
01

Why it matters

The higher price target and Buy rating could attract short‑term buying, but execution risk remains.

02

Market read

Analyst upgrade may provide a modest catalyst for SRRK and related biotech peers.

03

What to watch

Reimbursement uncertainty and fracture‑risk concerns could temper upside.

Relevance 4/10Novelty 2/10Timing: today

Background

Analyst houses reiterated bullish views on Scholar Rock after recent key opinion leader feedback on its SMA drug.

Company-level read

Ticker impact

$SRRKBullishMedium confidence
Context

Truist reiterated a Buy rating and raised its price target to $77 for Scholar Rock, citing new feedback from key opinion leaders on its Isembyld SMA treatment.

Expected impact

likely upward pressure as traders price in the higher target and positive clinical feedback

Evidence & confidence

The upgrade is fresh and includes a specific price target, which can influence short‑term demand.

Market effects

Positive sentiment may lift other biotech stocks focused on rare disease therapies.

US biotech sector could see modest gains.

Limited to investors tracking US-listed biotech.

Counterpoint

The upgrade may be premature if trial data does not translate into commercial sales.

Key entities

  • Truist Securities

    Reiterated Buy rating and $77 price target for SRRK.

  • Scholar Rock

    Biotech firm developing Isembyld for spinal muscular atrophy.

Related articles

$SRRKMedAI 8/10

Scholar Rock (SRRK) Q3 2026 Earnings Call Transcript

Scholar Rock (SRRK) reported Q3 2026 earnings, highlighting FDA approval of ISEMBYLD for SMA, a $205M deal for a priority review voucher, and progress in Japan and Phase II FORGE study. ISEMBYLD showed a 2.2-point motor function improvement in trials, with strong early launch demand. The company reported $0.6M in ISEMBYLD revenue and $413.6M in cash, with no immediate need for equity offering.

$SRRKLow

What Scholar Rock (SRRK) Said on Its Q3 Earnings Call

Scholar Rock (SRRK) reported Q3 earnings, noting no demand impact from a bone fracture warning. The company resubmitted its European marketing application for apitegromab, expecting a decision in early 2027. It anticipates a 2027 launch in Japan and Germany. Operating expenses were $106.6M, with $413.6M in cash. SRRK sold a priority review voucher for $205M and has access to an additional $150M under its debt facility.

$SRRKHighAI 8/10

Raymond James reiterates Strong Buy on Scholar Rock stock after Q3 results

Raymond James maintained a Strong Buy rating and $72.00 price target for Scholar Rock (NASDAQ: SRRK) after its Q3 2026 results. The stock is up 17% this week and 76% over the past year. Scholar Rock reported its first product revenues for ISEMBYLD, which received FDA approval in September 2026. The company's EPS beat estimates but revenue missed expectations, falling 60.14% short of forecasts.